The median time of recurrence-free survival was 44.0 months in the immunotherapy group and 30.0 months in the control group ( hazard ratio with immunotherapy , 0.63 ; 95 % confidence interval [ CI ] , 0.43-0 .94 ; P = .010 by 1-sided log-rank test ) .